HRE Luciferase Reporter Lentivirus

Catalog #
78668
$835 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Hypoxia Response Element (HRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of a hypoxia response elements (HRE) located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the induction of hypoxia in the target cells can be monitored by measuring the luciferase activity.

Figure 1. Schematic of the lenti-vector used to generate the HRE luciferase reporter lentivirus.

Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer >107 TU/ml. The titer will vary with each lot; the exact value will be provided with each shipment.
Materials Required But Not Supplied
Name Ordering Information
HEK293 ATCC #CCL-1573
Thaw Medium 1 BPS Bioscience #60187
96-well tissue culture, clear-bottom, white plate Corning #3610
ONE-Step™ Luciferase Assay System BPS Bioscience #60690
Luminometer  
Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

Background

Hypoxia occurs in solid tumors as a result of poor vascularization within the core of the tumor. It is a driver of tumor progression and resistance to therapy through adaptive responses. Hypoxia response elements (HREs) are transcription factor binding sites within the promoters of various genes regulated by hypoxia-inducible factors (HIFs). As oxygen becomes rate limiting, HIFs form heterodimers that recognize cognate HREs, thus activating the transcription of genes involved in cell proliferation, metastasis, and angiogenesis. HIF activation in many types of cancer correlates with poor outcomes.